GenEditBio Wins FDA IND Clearance for GEB-101 in TGFBI Corneal Dystrophy

The FDA has cleared GenEditBio's investigational new drug application for GEB-101, an in vivo genome-editing therapy for TGFBI corneal dystrophy, the company announced on January 5, 2026. The clearance enables the Phase 1/2 CLARITY trial, in which participants receive a single intrastromal injection, with enrollment expected to begin in the second quarter of 2026 after US site activation.

How is GEB-101 delivered to the eye?

GEB-101 is an in vivo genome-editing therapy delivered as a ribonucleoprotein administered directly into the corneal stroma, per the company's announcement. That delivery choice places it outside the two dominant gene therapy vector families: no adeno-associated viral vector carrying a DNA payload, and no lipid nanoparticle carrying mRNA. A ribonucleoprotein brings the editing enzyme and its guide RNA as a pre-assembled complex, intended to act and degrade without the genetic material persisting in cells.

The cornea makes local delivery unusually practical among tissues. It is optically accessible, immunologically privileged relative to other sites, and the pathology of TGFBI dystrophy, mutant TGFBI protein accumulating in the corneal stroma, sits in the compartment where the injection lands. The therapy is intended for corneal dystrophy related to mutations in the TGFBI gene, per coverage of the clearance by CGTlive. The company describes GEB-101 as a first-in-class program in this indication; that is a company claim at this stage, with no clinical data yet disclosed.

What does the CLARITY trial look like?

Per the company's release, the Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients with TGFBI mutation. The study has a seamless, adaptive, multicenter, sequential design, and trial participants receive a single intrastromal injection of GEB-101. Patient enrollment is expected to commence in the second quarter of 2026 after site activation in the US.

A seamless adaptive design means dose and cohort decisions are made on accumulating data rather than between separate protocol stages, which shortens the path from first-in-human exposure to expansion in a small indication. The primary lens, as with any first-in-human editing program, is safety at the injected tissue; efficacy signals in corneal clarity measures would be exploratory until the trial reports.

Why does an IND clearance matter here?

An IND clearance is the FDA's notification that a company may proceed with dosing humans in the US; it is not an approval and implies no judgment on efficacy. For GenEditBio, a clinical-stage startup, it is the transition of the lead program from bench to clinic, and for the field it adds a non-viral, locally delivered editor to the small set of in vivo editing programs in human testing. The company's January 5 announcement and trade coverage in CGTlive's January 7 roundup are the primary disclosures; trial registration details will follow on the public registry once listed.